Geron Corporation (GON)
Summary
GON Chart
Geron: Time To Reconsider This Oversold Biotech
Geron has secured FDA approval for RYTELO in low- to intermediate-1 risk MDS, marking a pivotal milestone after decades of development. Despite disappointing initial RYTELO sales, GERN forecasts 2026 revenues of $220–$240 million and is executing targeted commercial and European expansion strategies. A new management team is in place, with significant liquidity ($341 million) and a cash runway of ~2.7 years supporting ongoing pipeline and commercial efforts.
Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Geron (GERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Geron Corporation (GON) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Geron Corporation ever had a stock split?
Geron Corporation Profile
| Biotechnology Industry | Healthcare Sector | Harout Semerjian CEO | XDUS Exchange | US3741631036 ISIN |
| US Country | 229 Employees | - Last Dividend | 22 Jul 2014 Last Split | 30 Jun 1996 IPO Date |
Overview
Geron Corporation stands out as a pivotal entity within the biopharmaceutical sector, primarily focusing its efforts on the advanced clinical development and potential commercialization of treatments targeting myeloid hematologic malignancies. Marking its inception in 1990, Geron Corporation has since dedicated itself to addressing the urgent need for innovative therapeutic options within this specialized area of oncology. The company’s strategic operations and research endeavors are centralized in its headquarters located in Foster City, California. Geron's commitment to the field is underscored by its relentless pursuit of groundbreaking therapeutic advancements, aiming to significantly impact patients' lives afflicted by these severe blood disorders.
Products and Services
Geron Corporation's developmental pipeline is focused primarily on the pioneering therapeutic candidate, imetelstat. This telomerase inhibitor represents a novel approach in the treatment of myeloid hematologic malignancies. The significance of imetelstat lies in its mechanism of action, which targets the root cause of disease proliferation at the cellular level. Below are the key areas of focus for Geron's imetelstat:
- Low or Intermediate-1 Risk Myelodysplastic Syndromes: Imetelstat is in Phase 3 clinical trials for treating patients diagnosed with low or intermediate-1 risk myelodysplastic syndromes (MDS). This group of disorders adversely affects the bone marrow's ability to produce healthy blood cells, leading to various complications. The ongoing trials aim to evaluate the efficacy of imetelstat in controlling disease progression, potentially altering the treatment landscape for MDS patients.
- Intermediate-2 or High-Risk Myelofibrosis: Another critical area under investigation involves patients with intermediate-2 or high-risk myelofibrosis. This rare, chronic blood cancer is characterized by the extensive scarring of bone marrow, which disrupts the body's normal production of blood cells. By inhibiting telomerase activity, imetelstat seeks to counteract the uncontrolled proliferation of malignant stem and progenitor cells that contribute to the disease state, offering hope for a therapeutic breakthrough in the management of myelofibrosis.
